RMAT

In: Finance

JHVEPhoto Longeveron (NASDAQ:LGVN) shares climbed in the morning hours Wednesday after the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for its lead asset Lomecel-B as a treatment for mild Alzheimer’s. Targeted at regenerative medicines, including cell therapies such as Lomecel-B, the RMAT designation offers regulatory benefits similar toContinue Reading

In: Finance

JHVEPhoto Humacyte (NASDAQ:HUMA) stock rallied 19% Monday on news that the company has received FDA regenerative medicine advanced therapy, or RMAT, designation for its product candidate Acellular Tissue Engineered Vessel, or ATEV, for the treatment of peripheral artery disease. The biotech company noted it was the third RMAT designation forContinue Reading